Home | The Community

Go Back   Hypertrophic Cardiomyopathy Association™ Community > HCM Support Forums > Medications

Notices

Medications Nearly all of those with HCM are on some type of medical management. Share your thoughts, questions and concerns with others regarding medications here.

Reply
 
Thread Tools Display Modes
  #1  
Old 10-24-2005, 02:27 AM
cabb cabb is offline
Contributor-in-Training
 
Join Date: Sep 2005
Location: DePere Wisconsin
Posts: 5
Default Losartan

Hello,

I am hoping to find someone that has taken or at least heard of someone taking losartan. I was suppose to be a part of a study in D.C. for the benefits of losartan for patients that have non-obstructive HCM. I did not make the study because when I was there I had to come off my meds that I usually take (80mg inderal 3x a day, 200 mg norpace 3x day) and after 48 hrs I was immobile and had to be put back on my meds because incredible amount of chest pain. (this was in 97).

This past March I was told that I needed a ICD and they started me on losartan, saying that it should help make my heart more flexible and it should be able to pump more efficiently. I have been taking it but I really don,t like it,(it makes me very light headed for a period of time).
Reply With Quote
  #2  
Old 10-24-2005, 08:21 AM
williamm williamm is offline
Shy Heart
 
Join Date: May 2005
Location: Sao Paulo, Brazil
Posts: 21
Default

Dear cabb,

I am in a similar study in Brazil and started using Losartan about six months ago. I was on Nadolol before the study and didn't need to stop it or change the daily dose from that med. I've experienced no side effects. This study started in Brazil in 2003 and is still in phase 1. The parameters being monitored are the usual for HCM with special care for: atrial diameter, mitral velocities (E, A) with tissue doppler, BNP. The first published data results were good bettering all the monitored parameters. The study now is evaluating the fibrosis with MRI at six months interval. Obviously the gradient (even drug induced) needs to be carefully monitored because Losartan as any vasodilatators can exacerbate the gradient due the afterload reduction. The study aims to evaluate the role of AT2 blocking because its profibrotic effect is very known. This way, the vasodilatation is not a desired effect and, if not monitored, can be a side effect. Here in Brazil, all the recruited patients were non-obstructive also (lower than 30mmHg resting gradient) and there was no one that worsened their values.

The NHLBI has been concluded in 2003 another study with the same drug but the data still has not been published to my knowledge. The link from it is below:

http://www.clinicaltrials.gov/ct/show/NCT00001534

Regards,

William.
Reply With Quote
  #3  
Old 10-24-2005, 10:02 AM
Lisa Salberg's Avatar
Lisa Salberg Lisa Salberg is offline
HCMA President

 
Join Date: Dec 2002
Location: Hibernia, New Jersey
Posts: 6,076
Default

The study was terminated due to several issues. They never published results. The Internal Review Board -IRB of the NIH-NHLBI held several meetings on this matter and stopped the study due to violations of the standards of conducting research. This is one of the core reasons the HCM program at the NIH was disbanded.

Lisa
__________________
Knowledge is power ... Stay informed!
YOU can make a difference - all you have to do is try!
Reply With Quote
Reply

Bookmarks


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -4. The time now is 07:04 PM.


Powered by vBulletin® Version 3.8.5
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.
Website Content Copyright ©2008 Hypertrophic Cardiomyopathy Association™
Page generated in 0.43447 seconds with 9 queries